G
Gregory K. Pennock
Researcher at University of Texas MD Anderson Cancer Center
Publications - 15
Citations - 709
Gregory K. Pennock is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Soft tissue sarcoma & Olaratumab. The author has an hindex of 7, co-authored 13 publications receiving 630 citations.
Papers
More filters
Journal ArticleDOI
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
William D. Tap,William D. Tap,Robin L. Jones,Robin L. Jones,Brian A. Van Tine,Bartosz Chmielowski,Anthony D. Elias,Douglas Adkins,Mark Agulnik,Matthew M. Cooney,Michael B. Livingston,Gregory K. Pennock,Meera Hameed,Gaurav D. Shah,Amy Qin,Ashwin Shahir,Damien M. Cronier,Robert Ilaria,Ilaria Conti,Jan Cosaert,Gary K. Schwartz +20 more
TL;DR: An open-label phase 1b and randomised phase 2 study of doxorubicin plus olaratumab treatment in patients with unresectable or metastatic soft-tissue sarcoma at 16 clinical sites in the USA, finding progression-free survival in phase 2 was 6.6 months and the efficacy was assessed.
Journal ArticleDOI
Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma: How Different are these From Conventional Treatment Responses?
TL;DR: Patients on ipilimumab may have delayed responses or durable stable disease even after apparent disease progression, therefore using new immune-related response criteria is recommended to avoid premature treatment withdrawal.
Journal ArticleDOI
An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
Patrick Schöffski,Douglas D. Adkins,Jean-Yves Blay,Thierry Gil,Anthony D. Elias,Piotr Rutkowski,Gregory K. Pennock,Hagop Youssoufian,Hans Gelderblom,R. R. Willey,Dmitri Grebennik +10 more
TL;DR: Patients with adipocytic sarcoma may benefit from treatment with cixutumumab, and treatment was well tolerated, with limited gastrointestinal AEs, fatigue and hyperglycaemia.
Journal ArticleDOI
A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor {alpha} (PDGFR{alpha}) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS).
William D. Tap,Robin L. Jones,Bartosz Chmielowski,Anthony D. Elias,Douglas Adkins,Brian A. Van Tine,Mark Agulnik,Matthew M. Cooney,Michael B. Livingston,Gregory K. Pennock,Amy Qin,Ashwin Shahir,Robert Ilaria,Ilaria Conti,Jan Cosaert,Gary K. Schwartz +15 more
TL;DR: A phase Ib, open-label, randomized phase II study of Dox ± olaratumab in unresectable/metastatic STS, finding that Olaratumab enhances Dox activity in preclinical sarcoma models and is confirmed safe in phase Ib.
Journal ArticleDOI
Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft-tissue sarcoma and Ewing family of tumors.
Patrick Schöffski,Douglas Adkins,J.-Y. Blay,Thierry Gil,Anthony D. Elias,Piotr Rutkowski,Gregory K. Pennock,Hagop Youssoufian,N. J. Zojwalla,R. Willey,Dmitri Grebennik +10 more
TL;DR: Cixutumumab monotherapy was well tolerated with limited Grade 3 hyperglycemia and warrants further evaluation in this disease setting.